Prof. Hermann Luebbert, PhD, is Chief Executive Officer of Biofrontera AG and Managing Director of all its subsidiaries. He studied biology in his native city of Cologne, where he completed a PhD in 1984.
After eight years of academic research at the University of Cologne and the California Institute of Technology (USA), he was awarded the habilitation at the ETH (Eidgenössische Technische Hochschule) Zürich. Prof. Lübbert has held the Chair of Animal Physiology at Ruhr-University Bochum since 1998. During his ten years at Sandoz and Novartis Pharma AG, Prof. Lübbert acquired experience in managing a globally active research organisation.
He founded Biofrontera in 1997 and has since managed the company.
Erica Monaco serves as Chief Financial Officer for Biofrontera Inc. and is responsible for the financial stewardship and operational oversite of finance, operations, legal, compliance and human resources. She joined Biofrontera in 2016 and has accepted progressive positions culminating in her appointment to the Board of Directors of Biofrontera Inc., in January 2020. Erica has provided leadership and has been a key contributor in the success of the United States subsidiary of Biofrontera AG, from the earliest stages including the launch of the flagship products to the development of the business structure, processes and partnerships required to operate and grow the subsidiary into a $25M entity in 3 years. She was integral to the 2018 NASDAQ listing and the 2019 merger and integration of Cutanea Life Sciences. Erica is a Certified Public Accountant bringing 15 years of experience in diverse accounting and financial leadership roles, including audit and tax services with the public accounting firm Deloitte, where she worked with multiple global public companies on diverse projects. She has held corporate finance leadership roles within the pharmaceutical industry and not-for-profit entities, leading teams through accounting system implementations, organizational synergy projects and strategic planning initiatives. Erica received her Bachelor of Business Administration with an Accounting concentration and her Master of Accountancy (M.S.A) from The Isenberg School of Management at the University of Massachusetts.
Dr. Montserrat Foguet is Senior Vice President for Regulatory Affairs and Technical Operations. She is responsible for the registration dossiers of drug products and carrying out negotiations with regulatory agencies, such as EMA and FDA, necessary to obtain or maintain marketing authorisation for Biofrontera’a drug products. Within the Technical Operations department, she oversees global activites regarding the manufacture and supply chain of drug substances, drug products and cosmetics. Montserrat has more than 30 year experience in the pharma industry and is an expert in pharmaceutical nanoemulsions. She is in charge of the analytical and pharmaceutical development laboratory where innovative formulations with nanoemulsions and drug substances are developed and further investigated for Biofrontera’s internal research projects. She studied chemistry and biochemistry at the Autonomous University of Barcelona (Spain). She received a PhD from the University of Basel (Switzerland) and a Certificate on International Regulatory Affairs from the Northeastern University of Boston (USA). After several years of academic research at the Biocenter of the University of Basel, she accepted a position as scientist at the Preclinical Research Department at Novartis Pharma AG. In 1997, she joined Biofrontera as founding member where she has been appointed different positions within the R&D and Production teams culminating with her current position as Senior Vice President.
Wiebke Meyer-Wendt, PhD, joined Biofrontera in 2008 as scientist in preclinical research. Two years later, she was appointed as Head of Quality Management. In this role, she established the quality management system of Biofrontera during the change of Biofrontera’s business focus from research towards manufacturing and distribution in 2010. With the incorporation of a Global Quality Unit in 2019, she took over responsibility for the establishment, implementation and maintenance of all quality related functions of Biofrontera in the US and Europe. As Vice President Quality Management, she is in charge of Biofrontera’s concept of quality management that ensures that Biofrontera’s medicinal products and medical devices are manufactured so that they are fit for their intended use, comply with the requirements of the Marketing Authorization or Clinical Trial Authorization and do not place patients at risk due to inadequate safety, quality or efficacy.
In his role as Vice President Information Technology, Armin Ollig is responsible for developing and implementing the IT strategies required to drive and support the growth of Biofrontera internationally. He joined the company in 1999 and developed an advanced biological decision support system for drug-target identification. As the company grew, Armin built the requisite solutions to commercialize company-developed products and designed systems to expand data management across the globe. He brings a deep understanding of software engineering and a holistic perspective towards IT, and leads a team with a proven track record of developing and improving business processes.
Christopher Almeida, Head of Market Access & Trade, is responsible for the planning and execution of Biofrontera Inc.’s market access, reimbursement, and distribution strategies, including the securing of access for current and future products among US payers. Christopher joined Biofrontera Inc. in October 2018, as Director of Market Access. He brings more than 27 years of industry experience through a variety of roles, including 15 years of experience directly related to managed markets Prior to joining Biofrontera, Christopher was National Account Director at Purdue Pharma, overseeing commercial payer contracts, across several books of business, for brands in the analgesic, antimicrobial, gastroenterology, and sleep categories. He also held various corporate appointments, including seats on the Managed Markets Advisory Council and the Budget Impact Committee where he focused on market access strategy development, contract modification, and pull-through implementation. He previously served in clinical liaison, sales and marketing roles at Abbott Laboratories and Muro Pharmaceuticals. Christopher earned his B.A. from the University of California Los Angeles.
Daniel Hakansson joined Biofrontera Inc. as Corporate Counsel in January 2019. As Corporate Counsel, Dan is responsible for advising Biofrontera Inc.’s leadership team on corporate governance, contracts, compliance, business policy and other various legal matters. He was also appointed as Head of Compliance in November 2019. In this role, Dan leads the oversight, growth, and expansion of Biofrontera’s commercial compliance program. Prior to joining Biofrontera, Dan worked as a litigation attorney at a private law firm where he represented clients in many practice areas and specialized in Employment Law. During his tenure at the firm, Dan was a key member of the legal team who successfully represented a medical device component manufacturer in a highly contentious and precedent setting trade secret defense. He also has experience working with the Hillsborough County Attorney’s Office, the New Hampshire Commission for Human Rights and as a student clerk for a New Hampshire Supreme Court justice. Dan received his Juris Doctorate from the University of New Hampshire School of Law, where he was a member of the Daniel Webster Scholars Honors program. He also received a B.A. in Political Science from the University of Massachusetts – Amherst.
Erica Gates joined Biofrontera Inc. in August 2019 as the Corporate Controller. She is responsible for overseeing all aspects of financial reporting and the related accounting and control strategies and activities. Prior to joining Biofrontera Inc., Erica gained over ten years of progressive experience in both the pharmaceutical and financial services industries after beginning her career in public accounting at Caturano and Company in the audit practice. She brings significant experience in accounting policy, operations and strategy including extensive experience with public company reporting requirements. Most recently, Erica served as the Corporate Accounting Manager at Affiliated Managers Group, Inc. where she was responsible for management of financial accounting and treasury functions within a complex business structure while ensuring compliance with foreign and domestic regulatory requirements. Erica received a M.S. in Accountancy and M.B.A. from Northeastern University and has been a Certified Public Accountant since September 2009.
Biofrontera Inc. is a wholly owned subsidiary of Biofrontera AG. Biofrontera AG has two separate boards of directors, the Supervisory Board and the Management Board. No individual may simultaneously be a member of both boards. The Management Board is responsible for the day-to-day management of all subsidiaries of Biofrontera AG. The principal responsibility of the independent Supervisory Board is to supervise the Management Board as well as to appoint and remove members of the Management Board.